Floatz logo

Debio 1143

Adenocarcinoma of the Rectum

Centre Leon BerardPhase 1Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
89/ 100

Competitive context

42 Active assets in the Adenocarcinoma of the Rectum cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Merck Sharp & Dohme LLC
Phase 3BBB
Eloxatin
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3BBB
Irinotecan
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BBB
Eloxatin
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB
Cetuximab
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3BB

View all 50 →

Same molecule, other indications

Debio 1143 is also rated in:

neoplasmDormant
CCC
Indicative ·
49 / 100
View asset →
neoplasmDormant
CC
Indicative ·
47 / 100
View asset →
pancreatic adenocarcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →